Elite Pharmaceuticals

Elite Pharmaceuticals

Nasrat Hakim founded Elite Pharmaceuticals in 1997, building the company into a publicly traded specialty pharmaceutical manufacturer focused on generic drugs. The firm has operated from its headquarters and manufacturing facility in Northvale, New Jersey since inception. Unlike many asset-light pharmaceutical marketing companies, Elite chose to own its manufacturing capabilities directly—a decision that shapes its regulatory and operational footprint to this day. The company's strategy concentrates on developing Abbreviated New Drug Applications (ANDAs) for niche generic products, particularly those where manufacturing complexity or regulatory hurdles limit competition. Its portfolio includes generic versions of Adderall XR, OxyContin (abuse-deterrent formulation), and hydromorphone HCl. Beyond generics, Elite has pursued the development of SequestOx, its own branded abuse-deterrent oxycodone product, and has partnered with distribution companies to commercialize its approved products in the United States market. The pipeline historically included multiple pain management and central nervous system products at various stages of FDA review. Elite has operated with a modest team relative to its manufacturing ambitions, navigating the capital-intensive generic drug landscape as a micro-cap public company. The firm has maintained a lean operational structure, outsourcing certain sales and marketing functions while retaining direct control over research, development, and manufacturing in its New Jersey facility. Elite has periodically raised capital through public equity offerings to fund its ANDA pipeline and litigation costs associated with Paragraph IV patent challenges. The firm's structural differentiator lies in its direct ownership of a Drug Enforcement Administration (DEA)-licensed manufacturing facility capable of handling controlled substances—a significant operational moat in the abuse-deterrent opioid space. This vertical integration means Elite controls both the formulation technology and the physical production of its products, rather than relying on contract manufacturers, a posture that gives it a distinct regulatory and quality-control profile among small-cap generic drug makers.